@article{JTD20029,
author = {Francesco Passiglia and Luis E. Raez and Christian Rolfo},
title = {Moving osimertinib to first-line: the right “strategy” in the chessboard of epidermal growth factor receptor-mutated non-small cell lung cancer?},
journal = {Journal of Thoracic Disease},
volume = {10},
number = {Suppl 9},
year = {2018},
keywords = {},
abstract = {In the N Engl J Med, Soria and colleagues have recently reported the results of the phase III randomized FLAURA trial (1), comparing osimertinib with first generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) gefitinib or erlotinib in treatment-naive patients with advanced non-small cell lung cancer (NSCLC) and activating EGFR-mutations.},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/20029}
}